Hydroxyurea

Drug Overview

Hydroxyurea (also known as hydroxycarbamide) is a foundational antimetabolite and a potent ribonucleotide reductase inhibitor. Originally synthesized in the late 19th century, it has evolved into a cornerstone of modern hematology and oncology. It is primarily used to manage myeloproliferative neoplasms (MPNs) and sickle cell disease, acting as a “metabolic brake” on rapidly proliferating cell populations.

In the clinical landscape of 2026, hydroxyurea is celebrated for its versatility. While newer targeted therapies (like JAK inhibitors) have emerged, hydroxyurea remains the preferred first-line agent for many patients due to its predictable safety profile, low cost, and decades of documented efficacy. It is classified as an “S-phase specific” drug, meaning it is most toxic to cells that are actively synthesizing DNA, making it particularly effective against cancers with high turnover rates.

• Generic Name: Hydroxyurea (hydroxycarbamide).
• Brand Names: Hydrea, Droxia, Siklos.
• Drug Class: Antimetabolite; Ribonucleotide Reductase Inhibitor.
• Mechanism: Selective inhibition of DNA synthesis through the depletion of deoxyribonucleotide pools.
• Route of Administration: Oral (Capsules, tablets, or oral solution).
• FDA Approval Status: FDA-approved. It is listed on the World Health Organization’s List of Essential Medicines.

What Is It and How Does It Work? (Mechanism of Action)

Hydroxyurea functions as a biochemical “supply chain disruptor.” To understand its power, one must look at the way cells prepare for division during the S-phase (Synthesis phase) of the cell cycle.

1. Inhibition of Ribonucleotide Reductase (RR)

The primary target of hydroxyurea is the enzyme ribonucleotide reductase. This enzyme is the “rate-limiting” step in DNA production; it is responsible for converting ribonucleoside diphosphates into deoxyribonucleoside diphosphates. In simpler terms, it turns the basic components of RNA into the “bricks” (deoxyribonucleotides) needed to build DNA.

Hydroxyurea binds to the small subunit of the enzyme and neutralizes a tyrosine free radical that is essential for the enzyme’s function. Without a working RR enzyme, the cell’s internal supply of DNA building blocks dries up.

2. Molecular Level Effects

• DNA Synthesis Blockade: Without deoxyribonucleotides, DNA polymerase cannot continue building new genetic strands. This brings cell replication to a complete halt.
• DNA Repair Interference: Because the drug depletes the pool of nucleotides, the cell also loses its ability to repair damaged DNA. This makes hydroxyurea an excellent “sensitizer” for radiation therapy, as the radiation breaks the DNA, and the hydroxyurea prevents the cell from fixing it.
• Induction of Fetal Hemoglobin (HbF): In patients with Sickle Cell Anemia, hydroxyurea works through a different pathway (likely involving nitric oxide and soluble guanylyl cyclase). It stimulates the production of Fetal Hemoglobin, which does not “sickle.” This prevents the red blood cells from collapsing into the crescent shapes that cause blockages in blood vessels.

FDA Approved Indications

Hydroxyurea is utilized across a wide spectrum of malignant and non-malignant conditions. Its primary goal is cytoreduction lowering the number of cells in the blood to safe levels.

1. Myeloproliferative Neoplasms (MPNs)

• Polycythemia Vera (PV): Used to lower the red blood cell count and reduce the risk of stroke or heart attack caused by “thick” blood.
• Essential Thrombocythemia (ET): Used to lower extremely high platelet counts (often over 1,000,000/μL) to prevent blood clots.
• Chronic Myeloid Leukemia (CML): Traditionally used to rapidly lower white blood cell counts in the “chronic phase” before a patient starts more specific tyrosine kinase inhibitors.

2. Solid Tumors

• Head and Neck Cancer: Specifically Squamous Cell Carcinoma. It is used alongside radiation therapy to treat locally advanced tumors that cannot be removed by surgery.

3. Hematology (Non-Cancer)

• Sickle Cell Anemia: Used to reduce the frequency of painful “crises” and the need for hospitalizations in both pediatric and adult patients.

Dosage and Administration Protocols

Dosing for hydroxyurea is highly dynamic. Physicians often use a “start low and go slow” approach, adjusting the dose every few weeks based on the patient’s blood counts.

Handling and Administration

Because hydroxyurea is a cytotoxic (cell-killing) agent, it requires special handling.

• Caregivers should wear disposable gloves when handling the medication.
• Capsules must be swallowed whole; they should not be opened or crushed, as the powder can irritate the skin and lungs.
• Missed Doses: If a dose is missed, it should be skipped rather than doubled the next day.

Safety Profile and Side Effects

The therapeutic window of hydroxyurea is narrow. The difference between a “working dose” and a “toxic dose” is small, requiring constant vigilance.

1. Myelosuppression (Boxed Warning)

The most significant side effect is a drop in blood counts. This can lead to:

• Leukopenia: Low white blood cells, increasing the risk of life-threatening infections.
• Thrombocytopenia: Low platelets, leading to easy bruising or internal bleeding.
• Anemia: Low red blood cells, causing extreme fatigue.

2. Secondary Malignancies

There is a long-standing clinical debate regarding the “leukemogenic” potential of hydroxyurea. While the risk is low, long-term use (over 10 years) has been associated with an increased risk of developing Acute Myeloid Leukemia (AML) or non-melanoma skin cancers.

3. Dermatological and Mucosal Toxicity

• Skin Ulcers: Specifically “leg ulcers” near the ankles. These can be extremely painful and often require the medication to be stopped entirely to heal.
• Stomatitis: Painful mouth sores that can make eating difficult.
• Hyperpigmentation: Darkening of the skin and nails.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, hydroxyurea is being used to study “Stem Cell Quiescence.” By suppressing the active, rapidly dividing cells in the bone marrow, researchers are investigating how “dormant” or “quiescent” healthy stem cells can be protected during bouts of chemotherapy.

In 2026, there is also significant interest in the “Hydroxyurea-Immunotherapy Synergy.” Some studies suggest that by lowering the “bulk” of a tumor and reducing the number of immunosuppressive myeloid cells, hydroxyurea may actually make modern PD-1 inhibitors more effective in certain solid tumors.

Patient Management and Practical Recommendations

Essential Monitoring

• The “Weekly CBC”: During the first month of treatment, a Complete Blood Count (CBC) is required weekly to ensure the marrow is not being over-suppressed.
• Continuous Glucose Monitoring (CGM) Caution: In 2026, it is critical to note that hydroxyurea can interfere with certain CGM sensors (like Dexcom or Libre), causing falsely high glucose readings. Patients with diabetes must confirm their sugar levels with a finger-stick test.

“Do’s and Don’ts” List:

• DO wear high-SPF sunscreen daily. Hydroxyurea makes the skin highly sensitive to UV damage, increasing skin cancer risks.
• DO maintain high fluid intake (at least 2–3 liters per day) to help the kidneys process the drug and prevent uric acid buildup.
• DON’T get a “live” vaccine (such as the nasal flu spray or certain travel vaccines) while on this medication without consulting your hematologist.
• DON’T handle the medication if you are pregnant or planning to become pregnant; it is highly teratogenic (causes birth defects).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Hydroxyurea is a potent cytotoxic agent with significant risks. Always consult with a qualified oncologist or hematologist regarding your specific diagnosis and the management of your treatment plan.